The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: Determination of stroke subtype, severity and mortality

Journal of International Medical Research

Volumn 39, Issue 3, 2011, Pages 780-789

  Ustundag M ^a   Orak, M ^a   Guloglu C ^a   Tamam, Y ^a   Sayhan, M B ^b   Kale, E ^a  

^a DICLE UNIVERSITY   (Turkey)

^b State Hospital   (Turkey)

Author keywords

Ischaemic stroke; Mortality; S 100 protein; Steoprotegerin; Stroke severity

Indexed keywords

OSTEOPROTEGERIN; PROTEIN S 100;

AGED; ARTERY THROMBOSIS; ARTICLE; ATHEROTHROMBOTIC STROKE; BRAIN ISCHEMIA; BRAIN VENTRICLE; CARDIOEMBOLIC STROKE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; INTRACARDIAC THROMBOSIS; LACULAR STROKE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROPATHOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SURVIVAL RATE; TRANSIENT ISCHEMIC ATTACK;

EID: 80052197254     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900310     Document Type: Article

References (27)

1. Hankey GJ, Sudlow CL, Dunbabin DW: Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2000; 2: CD001246.
2. Diener HC, Cunha L, Forbes C, et al: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
3. Hårdemark HG, Ericsson N, Kotwica Z, et al: S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J Neurosurg 1989; 71: 727-731.
4. Mokuno K, Kato K, Kawai K, et al: Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. J Neurol Sci 1983; 60: 443-451.
5. Lamers KJ, van Engelen BG, Gabreëls FJ, et al: Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand 1995; 92: 247-251.
6. Hofbauer LC, Shui C, Riggs BL, et al: Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001; 280: 334-339.
7. Jono S, Ikari Y, Shioi A, et al: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194.
8. Rhee EJ, Lee WY, Kim SY, et al: Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 2005; 108: 237-243.
9. Schoppet M, Sattler AM, Schaefer JR, et al: Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-1028.
10. Guldiken B, Guldiken S, Turgut B, et al: Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 2007; 120: 511-516.
11. Bamford J, Sandercock P, Dennis M, et al: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-1526.
12. Adams HP Jr, Bendixen BH, Kappelle LJ, et al: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
13. Tatu L, Moulin T, Bogousslavsky J, et al: Arterial territories of human brain: brainstem and cerebellum. Neurology 1996; 47: 1125-1135.
14. Baird AE, Dambrosia J, Janket S, et al: A threeitem scale for the early prediction of stroke recovery. Lancet 2001; 357: 2095-2099.
15. Kiechl S, Schett G, Wenning G, et al: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180.
16. Oh ES, Rhee EJ, Oh KW, et al: Circulating osteo - protegerin levels are associated with age, waistto-hip ratio, serum total cholesterol, and lowdensity lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005; 54: 49-54.
17. Avignon A, Sultan A, Piot C, et al: Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005; 28: 2176-2180.
18. Browner WS, Lui LY, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-637.
19. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
20. Büttner T, Weyers S, Postert T, et al: S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 1997; 28: 1961-1965.
21. Herrmann M, Vos P, Wunderlich MT, et al: Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000; 31: 2670-2677.
22. Missler U, Wiesmann M, Friedrich C, et al: S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997; 28: 1956-1960.
23. Kim JS, Yoon SS, Kim YH, et al: Serial measurement of interleukin-6, transforming growth factor-β, and S-100 protein in patients with acute stroke. Stroke 1996; 27: 1553-1557.
24. Martens P, Raabe A, Johnsson P: Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. Stroke 1998; 29: 2363-2366.
25. Kenangil G, Yalçin AD, Haklar G, et al: Relation of serum S-100 protein to infarct size and clinical prognosis. Marmara Med J 2004; 17: 105-108.
26. Foerch C, Otto B, Singer OC, et al: Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004; 35: 2160-2164.
27. Rainer TH, Wong KS, Lam W, et al: Comparison of plasma β-globin DNA and S-100 protein concentrations in acute stroke. Clin Chim Acta 2007; 376: 190-196.